α-Glucosidase Inhibitors for Patients With Type 2 Diabetes

Abstract

OBJECTIVE -To review the effects of monotherapy with ␣-glucosidase inhibitors (AGIs) for patients with type 2 diabetes, with respect to mortality, morbidity, glycemic control, insulin levels, plasma lipids, body weight, and side effects. RESEARCH DESIGN AND METHODS -We systematically searched the CochraneCentral register of Controlled Trials, MEDLINE, EMBASE, Current Contents, LILACS, databases of ongoing trials, and reference lists, and we contacted experts and manufacturers. Inclusion criteria were randomized controlled trials of at least 12 weeks' duration, AGI monotherapy compared with any intervention, and one of the following outcome measures: mortality, morbidity, GHb, blood glucose, lipids, insulin levels, body weight, or side effects. Two independent reviewers assessed all abstracts, extracted all data, and assessed quality. We contacted all authors for data clarification. Continuous data were expressed as weighted mean differences and analyzed with a random-effects model. Possible influences of study characteristics and quality were assessed in sensitivity and meta-regression analyses.RESULTS -Forty-one studies were included in the review (30 acarbose, 7 miglitol, 1 voglibose, and 3 combined), and heterogeneity was limited. We found no evidence for an effect on mortality or morbidity. Compared with placebo, AGIs had a beneficial effect on GHb (acarbose Ϫ0.77%; miglitol Ϫ0.68%), fasting and postload blood glucose and postload insulin. With acarbose dosages higher than 50 mg t.i.d., the effect on GHb was the same, but the occurrence of side effects increased. Acarbose decreased the BMI by 0.17 kg/m 2 (95% CI 0.08 -0.26). None of the AGIs had an effect on plasma lipids. Compared with sulfonylurea, AGIs seemed inferior with respect to glycemic control, but they reduced fasting and postload insulin levels. For comparisons with other agents, little data were available.CONCLUSIONS -We found no evidence for an effect on mortality or morbidity. AGIs have clear beneficial effects on glycemic control and postload insulin levels but not on plasma lipids. There is no need for dosages higher than 50 mg acarbose t.i.d. Diabetes Care 28:166 -175, 2005A lpha-glucosidase inhibitors (AGIs; acarbose, miglitol, voglibose) are widely used in the treatment of patients with type 2 diabetes. AGIs delay the absorption of carbohydrates from the small intestine and thus have a lowering effect on postprandial blood glucose and insulin levels.In modern medicine, the efficacy of an intervention should be investigated in well-designed randomized trials. Results from the trials should be collected in a high-quality systematic review, if possible with a meta-analysis. And finally, the evidence should have its repercussions on practice guidelines.How does this apply for AGIs? Recommendations on when to use AGIs and the evidence used for these recommendations appear to be different in various guidelines. For example, the guideline by the European Diabetes Policy Group (1) and a consensus statement by the American Diabetes Association (2)...

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial

“…Because there is no evidence that acarbose affects glucose production directly, its effect to decrease FPG in the present study presumably reflects reduced glucose toxicity. The efficacy of both vildagliptin and acarbose monotherapy seen in the present study (ΔHbA 1c = −1.4 and −1.3%, respectively) was somewhat greater than is commonly seen with either agent (HbA 1c reductions of ~1.1% [13] and ~0.7% [18] with vildagliptin and acarbose, respectively). The reason for this became apparent when data from patients diagnosed > 3 months before enrolment were analysed separately.…”

Efficacy and Adverse Effects of Nateglinide in Early Type 2 Diabetes. Comparison with Voglibose in a Cross-over Study

“…In a recent prevention study of a wide spectrum of the disease from impaired glucose tolerance to type 2 diabetes using acarbose, 13% of the acarbose group prematurely discontinued the therapy due to gastrointestinal symptoms, compared with 3% of the placebo group [24]. In this regard, adverse drug events were reported to be more common in acarbose-treated patients than those on voglibose [16]. The reason for the preference of nateglinide as the choice drug in our study may depend on the frequency or severity of gastrointestinal adverse effects.…”

“…They reduce both postprandial hyperglycemia and hyperinsulinemia, and thereby may improve sensitivity to insulin and release the stress on pancreatic b-cells. These compounds do not induce hypoglycemia and have a good safety profile [16]; therefore they are widely prescribed for early type 2 diabetes patients in Japanese population. However, the gastrointestinal adverse effects of these drugs may limit long-term compliance to therapy.…”

In VITRO ANTIDIABETIC EFFECTS OF FERULA ASSA-FOETIDA EXTRACTS THROUGH DIPEPTIDYL PEPTIDASE IV AND Α-Glucosidase INHIBITORY ACTIVITY

“…DPP-IV rapidly destroys the incretin hormones, glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). These peptides are members of the glucagon peptide superfamily that helps the body produce more insulin when it is needed [1,[7][8][9][10][11].…”